Bobby W. Sandage, Jr.

President and Chief Executive Officer
Euclises Pharmaceuticals, Inc.

“I am deeply honored to be recognized by the College that provided me with the training and opportunity to build a successful career in the pharmaceutical industry. My time at the Purdue University College of Pharmacy not only provided me with the tools that I needed in my career but also led to life-long friends, colleagues and my wife of 37 years.”
  • BS 1975, Pharmacy, University of Arkansas
  • PhD 1981, Clinical Pharmacy, Purdue University
Career Highlights
  • Had the good fortune to have had a role in the approval of 14 drugs that have improved the lives of many patients
  • Led several start-up biotech companies and have taken one public
  • Served on numerous board of directors for both private and public companies
  • Mentoring many young entrepreneurs of various startup companies
  • Partner in venture capital firm financing promising start up life science companies

Bobby W. Sandage, Jr., Ph.D. is currently President and CEO of Euclises Pharmaceuticals, a private oncology company and General Partner in Cultivation Capital Life Sciences Fund II, a St. Louis venture fund. He has over 36 years of experience in the pharmaceutical industry in drug development and management. Previously he was President and CEO for Coronado Biosciences, Inc. (CNDO) where he led the effort to take the company public in 2011. Prior to that, he was VP of Covidien Pharmaceuticals’ oncology R&D program. For 19 years, Dr. Sandage was the CSO and EVP of Research & Development, quality and manufacturing at Indevus Pharmaceuticals, which was acquired by Endo Pharmaceuticals in 2009. Prior Indevus he held senior drug development positions at DuPont Merck Pharmaceutical Company, Merrell Dow and Dow Pharmaceuticals.

Dr. Sandage is a director of Immunophotonics, a private oncology company, Tensive Controls, a private biotech company and Mateon (MATN) a public oncology company. Previously he was director of Tioma (private oncology company), Gentium (GENT), an Italian biotech company, Osteologix, Inc. (OLGX) a Danish biotech company, Genta (GNTA) and Aeolus Pharmaceuticals.

Dr. Sandage is a member of the Dean’s Advisory Boards at Southern Illinois University Edwardsville (SIUE) School of Pharmacy and the University of Arkansas College of Pharmacy. He is an adjunct professor in the Department of Pharmaceutical Sciences at SIUE School of Pharmacy and has published over 50 scientific articles.

Dr. Sandage received his Ph.D. in Clinical Pharmacy from Purdue University and his B.S. in Pharmacy from the University of Arkansas. Dr. Sandage is a registered pharmacist.